Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 trial of Breast Cancer Vaccine in the neoadjuvant (before surgery) setting, in combination with chemotherapy and Keytruda (pembrolizumab)

Next Previous
Trial Profile

A phase 2 trial of Breast Cancer Vaccine in the neoadjuvant (before surgery) setting, in combination with chemotherapy and Keytruda (pembrolizumab)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 08 Nov 2024 According to Anixa Biosciences media release, the result data from NCT04674306 study provide the confidence to plan this Phase 2 study in the neoadjuvant setting with newly diagnosed breast cancer patients.
  • 24 Sep 2024 According to Anixa Biosciences media release, with the data obtained in this trial, we expect to conduct additional, more informed studies for both recurrence prevention and primary prevention with partners in the future.
  • 24 Sep 2024 According to Anixa Biosciences media release, the trial is expected to commence in 2025 and is projected to last approximately two to three years. Immunological responses to the vaccine will be made available as the trial advances, providing a faster and more cost-effective path toward potential approval and/or partnerships with pharmaceutical companies.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top